DoD Amyotrophic Lateral Sclerosis Research, Therapeutic Idea Award


Funding Opportunity ID: 310503
Opportunity Number: W81XWH-19-ALSRP-TIA
Opportunity Title: DoD Amyotrophic Lateral Sclerosis Research, Therapeutic Idea Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
CFDA Number(s): 12.420
Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:
Agency Code: DOD-AMRAA
Agency Name: Department of Defense
Dept. of the Army — USAMRAA
Posted Date: Nov 20, 2018
Close Date: Jul 25, 2019
Last Updated Date: Nov 20, 2018
Award Ceiling: $0
Award Floor: $0
Estimated Total Program Funding: $4,000,000
Expected Number of Awards: 5
Description: The Therapeutic Idea Award is designed to promote new ideas aimed at drug or treatment discovery that are still in the early stages of development. Projects that focus primarily on investigating the pathophysiology of ALS are not within the scope of this Funding Opportunity. Development and/or modification of preclinical model systems or the application of high- throughput screens to define or assess lead compounds for ALS treatment are of interest. Development of methods to adequately measure target binding and proximal downstream effects (target engagement) and the potential for undesirable activities at related but unintended targets (selectivity) are also encouraged. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative approach. All proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Innovation and impact are important aspects of the Therapeutic Idea Award. Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or technologies, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS. Impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Identification of treatment approaches using biological correlates of disease activity and progression in pre-existing, de-identified human specimens from well-characterized, adequately controlled, and sufficiently powered patient cohorts is encouraged. Examples of acceptable cohorts for study include controlled clinical trials, observational studies, and registries (e.g., Centers for Disease Control and Prevention [CDC] National ALS Registry and/or Biorepository; ( Active duty military and/or Veteran patient populations or resources should be considered. All specimens must exist at the time of application submission; collection of new specimens will not be supported. The Therapeutic Idea Award encourages applications that include meaningful and productive collaborations between investigators. As appropriate, applicants are encouraged to collaborate with established ALS researchers. Applicants seeking support for the development of products beyond drug or treatment discovery should consider the FY19 ALSRP Therapeutic Development Award (Funding Opportunity Number: W81XWH-19-ALSRP-TDA), which supports advanced preclinical development activities ( The anticipated direct costs budgeted for the entire period of performance for an FY19 ALSRP Therapeutic Idea Award will not exceed $500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
Version: 1

Visit the Official Webpage For More Details on DoD Amyotrophic Lateral Sclerosis Research, Therapeutic Idea Award


Please enter your comment!
Please enter your name here